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The protein p62/Sequestosome 1 (p62) has been described as a selective autophagy receptor 
and independently as a platform for pro-inflammatory and other intracellular signaling. How 
these seemingly disparate functional roles of p62 are coordinated has not been resolved. Here 
we show that TAK1, a kinase involved in immune signaling, negatively regulates p62 action in 
autophagy. TAK1 reduces p62 localization to autophagosomes, dampening the autophagic 
degradation of both p62 and of p62-directed autophagy substrates. TAK1 also relocalizes p62 
into dynamic cytoplasmic bodies, a phenomenon that accompanies the stabilization of TAK1 
complex components. On the other hand, p62 facilitates the assembly and activation of TAK1 
complexes, suggesting a connection between p62’s signaling functions and p62 body formation.  
Thus, TAK1 governs p62 action, switching it from an autophagy receptor to a signaling platform. 
This ability of TAK1 to disable p62 as an autophagy receptor may allow certain autophagic 





Activation of the macroautophagy pathway frequently accompanies a wide variety of 
cellular hazards including nutrient limitation, proteotoxic stress, damage to endolysosomal 
membranes, and detection of pathogens or pathogen-associated molecular patterns (PAMPs) 
[1-5]. Macroautophagy (hereafter referred to as autophagy) is a mechanism of cellular waste 
management and quality control in which cytoplasmic contents are packaged in a double 
membranous vesicle termed an autophagosome [6]. Typically, autophagosomes fuse with 
lysosomes resulting in the degradation of vesicular contents [6]. Several dozen proteins have 
been identified to have roles in autophagy in yeast. Higher organisms have a substantially larger 
repertoire of autophagy factors [7], possibly owing to the expanded physiological roles of 
autophagy in multicellular organisms.  
There are numerous connections between the autophagy machinery and other cellular 
stress response pathways. For example, activation of components of the NF-κB pathway can 
promote autophagy through several mechanisms [8-11]. TBK-1, a kinase required for activation 
of IRF-3 in response to viral infection, promotes autophagosome formation, maturation, and 
selective cargo recognition by the autophagy apparatus [12-15]. Furthermore, oxidative stress 
induces autophagy and promotes the expression of autophagy factors through activation of Nrf2 
dependent transcription [16]. One reason for the overlap between autophagy and these or other 
cell stress pathways is that autophagy can serve as an effector to eliminate the danger. For 
instance, damaged mitochondria, the source of oxidative stress, are eliminated by autophagy 
[17]. In contrast, certain components of the autophagy machinery can also promote 
inflammatory processes such as scaffolding the activation of RIPK1 and RIPK3 [18]. 
The intersections between cell stress pathways and autophagy are perhaps best 
illustrated by the protein p62/SQSTM1 (p62) [19,20]. On the one hand, p62 can act as a 
signaling hub with effects on PKC-zeta, PKC-iota, mTOR, caspase-8, Nrf2, and NF-κB signaling 
[21-28]. On the other hand, p62 is an autophagic adaptor that mediates the selective recognition 
and degradation of specific autophagy substrates including protein aggregates [29,30], 
intracellular bacteria [31], or specific proteins such as the Nrf2 inhibitor Keap1 [28]. Many of 
these substrates are flagged for autophagic degradation by an ubiquitin tag [32,33]. p62 
recognizes these tags via a C-terminal ubiquitin-binding domain (UBA), and bridges the 
substrate with LC3 proteins associated with the nascent autophagosome membrane [30,31,34]. 
Following delivery to the lysosome, p62 is co-degraded with its substrates [34]. The factors 
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controlling how p62 carries out its contrasting functions in inflammation and autophagy are not 
known. 
Interestingly, a variety of stress conditions are known to trigger a change in the 
localization of p62 from an overall diffuse cytoplasmic pattern to a punctate pattern [30,35]. 
Whereas p62 can self-assemble into coalesced structures in vitro [36], the fact that p62 bodies 
in cells primarily assemble in response to stress suggest that their formation is regulated in vivo. 
The factors which control p62 relocalization are not fully understood, nor is the physiological 
significance of p62 body formation to p62’s roles in autophagy or signaling. In this study, we 
sought to determine how p62 relocalizes to cytoplasmic bodies in response to cellular stress. 
We found that the inflammation-related protein TGF-β activated kinase 1 (TAK1, also MAP3K7) 
is required for p62 body formation under stress conditions that also induce autophagy. 
Nevertheless, p62 in these TAK1-generated bodies is resistant to autophagic degradation and 
thus is disabled in a key aspect of its role as an autophagy receptor. Indeed, while TAK1 
complexes are substrates of p62-directed selective autophagy, p62 body forming conditions 
spare TAK1 from degradation. Furthermore, under these conditions p62 acts as a platform 
assembling and activating TAK1 complexes. Thus, TAK1 tilts the balance of p62 activities away 





TAK1 is required for p62 body formation in response to stress conditions 
We developed a high content imaging-based assay to measure p62 body formation in 
cells. This assay involves the automatic imaging and unbiased analysis of thousands of cells, 
and thus confers substantial statistical power. We found that treatment of HeLa cells with the 
mTOR inhibitor pp242 for 1 hour increased both the number of p62 bodies (average surface 
area, 3.2 ± 0.2 µm2) and the total area of p62 bodies per cell (Fig. EV1A). We did not observe 
any effect of pp242 treatment on the abundance of poly-ubiquitin containing structures in cells 
(Fig. EV1B), suggesting that ubiquitin-binding is unlikely to explain pp242-stimulated p62 
relocalization. We considered a model in which phosphorylation of p62 could account for its 
relocalization to punctate structures. Because p62 is a known substrate for TBK1 [13,15] and 
ULK1 [37], we considered whether either of these kinases are required for p62 body formation. 
However, neither treatment of cells with the TBK1 inhibitor BX-795 nor knockdown of ULK1 
prevented the pp242-induced formation of p62 bodies; with ULK1 knockdown increasing their 
abundance (Fig. EV1C,D). The finding that p62 body formation is independent of ULK1 
indicates that the pp242-induced p62 bodies are not autophagosomes, the formation of which 
requires ULK1. As a third candidate, we tested the ubiquitin-sensing kinase TAK1 [38]. TAK1 is 
a serine/threonine kinase with key roles in inflammatory signaling cascades triggered by 
engagement of certain cytokine receptors or detection of pathogen-associated molecular 
patterns such as lipopolysaccharide (LPS) [39]. Interestingly, LPS stimulation of dendritic cells 
has previously been shown to induce the formation of cytoplasmic structures called DALIS that 
morphologically resemble p62 bodies and contain p62 [40,41]. We found that TAK1 knockdown 
by siRNA eliminated or substantially delayed p62 body formation in response to pp242 relative 
to cells transfected with control siRNA (Fig. 1A). TAK1 knockdown had no effect on p62 
abundance under unstimulated conditions when autophagy is operating at a basal level (Fig. 
EV1E). p62 bodies are also formed in response to other autophagy-inducing stressors including 
endolysosomal membrane damage induced by calcium phosphate precipitates (CPP) [3] or 
proteotoxic stress induced by the protein synthesis inhibitor puromycin [29]. As we observed 
with pp242, TAK1 knockdown also dramatically reduced the abundance of p62 bodies following 
CPP or puromycin treatment of HeLa cells (Fig. EV1F,G), indicating a general role for TAK1 in 
p62 body formation. Puromycin treatment promotes the p62-dependent formation of ubiquitin-
rich cytoplasmic puncta [29,40], a process substantially reduced by TAK1 knockdown (Fig. 1B-
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D). Together, these data show that TAK1 contributes to the formation of p62 bodies and to the 
ability of p62 to organize ubiquitylated targets in response to several cellular stresses. 
In order to be a functional kinase, TAK1 must interact with its essential co-factors TAB1 
and TAB2 (or TAB3). While TAK1 constitutively interacts with TAB1, binding with TAB2 is 
conditional with TAB2 recruited to TAK1 via K63-linked poly-ubiquitin chains [38]. K63-linked 
ubiquitin chains are generated by the E2 ubiquitin conjugating enzyme UBC13/UBE2N and can 
be directly conjugated to targets or released as free chains by a number of E3 ligases including 
TRAF6. We tested whether components of the TAK1 signaling pathway in addition to TAK1 
itself were involved in p62 body formation. Knockdown of UBC13, TRAF6, and TAB2 all 
reduced the abundance of p62 bodies, suggesting that factors upstream of TAK1 contribute to 
p62 localization (Fig. 1E; Fig. EV1H,I). In these experiments, we also knocked down the 
autophagy factor ATG7, which as expected did not affect p62’s localization to bodies nor did 
knockdown of TBK1. We next tested whether TAK1 activity is required for p62 body formation 
using the specific TAK1 inhibitor (5Z)-7-oxozeaenol (hereafter referred to as 5Z). Although 5Z 
treatment did not affect the abundance of p62 bodies under non-induced conditions, 5Z 
dampened the ability of pp242 to induce p62 bodies (Fig. 1F). Expression of GFP-tagged TAK1 
increased the abundance of p62 bodies in HeLa cells relative to cells expressing GFP alone 
(Fig. 1G). In these experiments, we observed substantial colocalization between GFP-TAK1 and 
p62 signals (Fig. EV2A), a result that we confirmed by confocal microscopy (Fig. EV2B). The 
ability of TAK1 expression to promote p62 body formation required TAK1 enzymatic activity, as 
expression of kinase-dead TAK1 (K63W) did not increase p62 bodies (Fig. EV2C,D) and GFP-
TAK1 (K63W)-positive structures showed less colocalization with p62 than did GFP-TAK1 (WT) 
(Fig. EV2C,E).  Together, these data show that the TAK1 signaling pathway and TAK1 activity 
are important for the formation of p62 bodies. 
TAK1 expression increases p62 phosphorylation 
Since phosphomimetic mutants of p62 at Ser403 are reported to enhance p62 body 
formation [42] and ubiquitin binding [37], we next tested whether TAK1 could influence 
phosphorylation at that site. TAK1 knockdown reduced the amount of p62 phosphorylated at 
Ser403 (Fig. 1H) while expression of GFP-TAK1 had the opposite effect and also increased p62 
phosphorylation at two other previously described sites (Thr269/Ser272 and Ser349; Fig. 
EV2F). We next took a phospho-proteomic approach to determine if TAK1 increased p62 
phosphorylation at additional sites. These experiments revealed that p62 phosphorylation was 
increased at Ser24 and at Ser226 in cells expressing GFP-TAK1 relative to cells expressing 
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GFP alone (Fig. 1I,J; Table 1). Phosphorylation of p62 at Thr269/Ser272 was detected in both 
GFP and GFP-TAK1 expressing cells, but the multiple phosphorylation events at this locus 
interfered with quantitative analysis (Fig. EV2H; Table 1). Phospho-peptides containing Ser349 
or Ser403 were not detected in either sample. Unlike wild type, expression of K63W mutant 
TAK1 did not increase, and in fact decreased, phospho-p62 abundance (Fig. EV2G). TAK1 
knockdown did not affect the ability of p62 to oligomerize (Fig. EV2I) or to bind ubiquitin (Fig. 
EV2J) in coimmunoprecipitation experiments, suggesting that TAK1 promotes p62 bodies 
through other mechanisms. These data indicate that TAK1 expression promotes 
phosphorylation of p62 at several sites including one previously implicated in body formation. 
TAK1 inhibits the autophagic degradation of p62 
 We anticipated that TAK1 likely plays a role in promoting the autophagic degradation of 
p62. However, we found the opposite, as p62 levels were reduced in cells subjected to TAK1 
knockdown following autophagy induction by amino acid starvation (Fig. 2A,B). These reduced 
levels of p62 were rescued by treatment with the autophagy inhibitor bafilomycin A1, indicative 
of enhanced autolysosomal degradation of p62 in the absence of TAK1. In contrast, we did not 
see effects of TAK1 knockdown on NBR1, a p62 homologue that is also an autophagic 
substrate [5]. Whereas TAK1 knockdown promoted the autophagic degradation of p62, TAK1 
expression had a protective effect on p62 levels in cells under amino acid starvation conditions 
(Fig. 2C,D; Fig. EV3A). This effect was not seen in bafilomycin A1 treated cells. Interestingly, a 
kinase-dead mutant of TAK1 (K63W) protected p62 from autophagic degradation similarly to 
WT TAK1 (Fig. 2C,D), suggesting that the p62-protective function of TAK1 is independent of its 
p62 body-forming function, the latter of which we found to require TAK1 activity (Fig. 1). 
Transient expression of TAK1 did not affect the abundance of p62 mRNA, suggesting a 
posttranslational role of TAK1 in p62 protection (Fig EV3B).  
 p62 delivery to the autophagosome is mediated through its interaction with the 
autophagosomal membrane-associated protein LC3B [30]. TAK1 expression reduced the 
abundance of LC3B in p62 protein complexes (Fig. 2E). As above, TAK1 kinase activity was 
dispensable for the ability of TAK1 to disrupt p62-LC3B interactions (Fig. EV3C). TAK1 
expression also reduced the localization of p62 to autophagosomes, with GFP-TAK1 positive 
p62 structures showing much reduced positivity for LC3B relative to GFP-TAK1-negative p62 
structures as determined by confocal microscopy (Fig. EV3D,E) and by high content imaging 
(Fig. 2F). These data suggested a model in which the TAK1-dependent p62 bodies are less 
susceptible to autophagy than other pools of p62. To test this model, we used high content 
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imaging to compare the effects of autophagy induction on the abundance of p62 bodies relative 
to the abundance of total p62, the latter determined by measuring the total anti-p62 signal per 
cell. In these experiments, both autophagy (Fig. EV3F) and p62 bodies (Fig. EV3G) were 
induced with pp242. Treatment of HeLa cells with pp242 rapidly induced p62 bodies, which 
showed a threefold induction by 15 minutes after treatment and became maximally induced (5-6 
fold) by 30 minutes following treatment (Fig. EV3G). The number of p62 bodies remained at this 
elevated level for the duration of the experiment (200 minutes). To quantitate the total 
abundance of p62, we measured the total above-background fluorescence of anti-p62 signal per 
cell (Fig. EV3G). As expected, pp242 treatment resulted in a reduction of p62 signal, first 
detectable at 90 minutes following treatment – long after maximal induction of p62 bodies. 
Importantly, although the total abundance of p62 continued to decline thereafter, the number of 
p62 bodies remained high. This result suggested p62 bodies (coalesced structures >3µm2) are 
more resistant to autophagic degradation than is the total pool of p62. Together, these results 
indicate that TAK1 prevents p62 from acting in selective autophagy by reducing its interaction 
with LC3B and by relocalizing it to cytoplasmic bodies. 
p62 interacts with TAK1 complexes  
 Since the effects of TAK1 on p62 are most pronounced under conditions promoting p62 
body formation (for example, following puromycin treatment or mTOR inhibition), we determined 
if mTOR-inhibitor pp242 treatment affected interactions between p62 and the TAK1 complex. 
Because p62 and TAK1 have already been reported to exist in protein complexes in cells [43], 
we focused first on the TAK1 cofactor TAB2. While we did not detect TAB2 in co-
immunoprecipitates with p62 under basal conditions, treatment of cells with pp242 strongly 
enhanced the abundance of TAB2 in complexes with p62 (Fig. 3A). In confocal microscopy 
studies, we found that GFP-TAB2 co-localized with endogenous p62 in cells treated pp242 (Fig. 
EV4A). These results suggest that p62 may bind to active TAK1 complexes consisting of both 
TAK1 and TAB2. The assembly of active TAK1 complexes requires K63-linked poly-ubiquitin 
chains produced by the ubiquitin conjugating enzyme UBC13 [39]. Knockdown of UBC13 
reduced the interaction between p62 and TAB2 (Fig. 3B; Fig. EV4B) or TAK1 (Fig. EV4C) in 
coimmunoprecipitation experiments. We next mapped the region of p62 responsible for its 
interactions with TAK1 complexes by assessing the ability of p62 deletion mutants to 
immunoprecipitate TAK1 or TAB2 (Fig. 3C,D; Fig. EV4D,E). In these experiments, we used the 
following three p62 deletion constructs: i) △PB1, an N-terminal deletion which disrupts p62’s 
ability to oligomerize and form puncta; ii) △UBA, a C-terminal deletion that eliminates p62’s 
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ubiquitin binding activity, and iii) △PB1△UBA, encompassing the middle of p62 and including 
motifs required for binding to LC3, TRAF6, and KEAP1 (Fig. 3C). As expected, GFP-tagged WT 
p62 immunoprecipitated TAK1 (Fig. 3D) and TAB2 (Fig. EV4E), as did GFP-p62△UBA. Deletion 
of the PB1 domain of p62 strongly reduced p62’s interaction with TAK1 (Fig. 3D) and TAB2 (Fig. 
EV4E), although we still observed above-background binding of both TAK1 and TAB2 to △PB1. 
This residual binding was lost when both the PB1 and UBA domains of p62 were deleted. In 
separate experiments, we found that p62’s PB1 domain on its own was not sufficient to 
immunoprecipitate TAK1 (Fig. EV4D). Together, these data suggest that p62 interacts with 
TAK1 complex components in a manner requiring its PB1 domain with contributions from the C-
terminal UBA domain (Fig. 3C). Confocal microscopy experiments indicated that the interaction 
between TAK1 complex components and p62 most likely occurs in the context of coalesced p62 
bodies, as we observed strong colocalization of tagged TAK1 and TAB2 with punctate p62 (Fig. 
3E). FRAP experiments indicate that these structures allow substantial exchange with the 
surrounding cytoplasm (Fig. EV4F). In these experiments, we observed a rapid, albeit partial, 
recovery in GFP-TAK1 signal following bleaching that is characteristic of structures referred to 
as signalosomes [44]. 
p62 targets TAK1 complex components for autophagic degradation 
We next asked if p62 contributes to the functions of TAK1 or TAB2. The finding that 
some TAK1-p62 double positive structures in cells were also positive for LC3B (Fig. 2F, EV5A) 
suggested that p62 may act as an autophagy receptor removing TAK1 complex components 
from cells. In accordance with this model, GFP-labeled TAB2 co-localized with LC3B positive 
structures when expressed in HeLa cells (Fig. 4A). Furthermore, we detected TAK1-TAB2 
double-positive structures that co-localized with LC3B in HeLa cells (Fig. 4B). We next used the 
tandem fluorescence approach [30] to determine if TAK1 and TAB2 are found within acidified 
compartments (lysosomes). To do this, we generated mCherry-eGFP tagged TAK1 or TAB2. 
Whereas eGFP fluorescence is lost under low pH conditions, mCherry fluorescence is retained. 
When expressed in HeLa cells, we found puncta from both TAK1 and TAB2 fusion proteins 
showing only red fluorescence under both full media and amino acid starvation conditions (Fig. 
4C, EV5B), suggesting that some of the TAK1 or TAB2 fusion proteins were within lysosomes. 
Treatment with bafilomycin A1 increased the abundance of TAK1, TAB2, and p62 under amino 
acid starvation-induced autophagy conditions (Fig. 4D). These data demonstrate that TAK1 and 
TAB2 are targets of autophagy. Autophagic targeting of TAK1 and TAB2 required p62, as p62 
knockdown increased their relative abundance (Fig. 4E). Importantly, inhibition of autophagic 
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flux by bafilomycin A1 abrogated the effect of p62 knockdown (Fig. 4E), suggesting that p62 
promotes the selective autophagic degradation of TAK1 and TAB2. In these experiments we 
also saw that knockdown of UBC13, which contributes to p62—TAK1 complex interactions, 
protected TAK1 and TAB2 from autophagic degradation (Fig. 4E). TLR3 is a double-stranded 
RNA (dsRNA) sensor that transduces signals via TAK1 to activate NF-κB- and AP1-driven gene 
expression [45]. We used a TLR3 reporter cell line to test how autophagic degradation of TAK1 
complexes affects TLR3 signaling and found that inhibition of autophagy by knockdown of 
Beclin 1 enhanced these cells’ responsiveness to the dsRNA analogue poly(I:C) [46] (Fig. 4F) 
and increased levels of TAB2 (Fig. EV5C). Taken together, these data demonstrate that TAK1 
complexes are substrates of p62-directed selective autophagy and that autophagy attenuates 
TAK1 signaling. 
p62 body formation protects TAK1 complexes from autophagy 
 The data above indicate that p62 is an autophagic receptor for TAK1 complexes, yet our 
findings also demonstrate that TAK1 promotes the formation of autophagy-resistant p62 bodies 
and antagonizes the activities of p62 in selective autophagy. Thus, we tested how p62 body 
formation affects the autophagic degradation of TAK1. In these experiments, we used p62 over-
expression as a surrogate for p62 body formation because we found that p62 over-expression 
increases the abundance of p62 bodies and that over-expressed p62 is preferentially localized 
to coalesced structures (Fig. EV5D). Increasing body formation by p62 over-expression 
corresponded with increased abundance of endogenous and over-expressed TAK1 in cells (Fig. 
5A; EV5E). However, expression of a mutant form of p62 that cannot form p62 bodies (△PB1) 
(Fig. EV5F) does not have this effect on TAK1 abundance (Fig. 5B). These data suggest that 
conditions favoring p62 body formation serve to spare TAK1 complexes from autophagic 
degradation.  
Antiviral factor TRIM5α stimulates p62 body formation and prevents autophagic degradation of 
TAK1 complexes in response to retroviral capsid 
 We next considered factors that could influence p62 body formation and thereby 
promote TAK1 signaling. We focused on the tripartite motif (TRIM) family of proteins as 
candidates. Like p62, TRIMs have important roles in both transducing immune activating signals 
[47] and in selective autophagy [48]. Moreover, several TRIMs are reported to interact with p62 
[49], and TRIM21 is reported to inhibit p62 body formation under conditions of proteotoxic stress 
[50] while TRIM17 increases the abundance of p62 bodies under basal conditions [51]. We 
performed an siRNA screen of human TRIMs to see if knockdown of any TRIM could reduce the 
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abundance of p62 bodies in HeLa cells (Fig. 5C). In addition to TRIM17, we identified 5 TRIMs 
which when knocked down reduced the abundance of p62 bodies and an additional 6 TRIMs 
whose knockdown had the opposite effect. Of the TRIM ‘hits’ where we saw a reduction in the 
number of p62 bodies upon knockdown, we chose to focus on TRIM5α since it has previously 
been reported to localize to p62 bodies [52] as well as interact with and activate TAK1 [53,54] 
and positively regulate autophagy [49]. In follow up experiments, we confirmed that knocking 
down TRIM5α reduced the number of p62 bodies (Fig. 5D). We next tested how TRIM5α 
knockdown affected the autophagic degradation of p62, TAK1, and TAB2 (Fig. 5E) and found 
that protein levels of p62, TAK1, and TAB2 were all reduced in TRIM5α siRNA-transfected cells 
under starvation-induced autophagy conditions. These experiments found that the effect of 
TRIM5 knockdown was partially autophagy-dependent as demonstrated by bafilomycin A1 
protection, but also indicate that additional mechanisms (e.g. transcriptional and/or 
proteasomal) also contribute to TRIM5’s ability to increase the protein levels of p62, TAK1, and 
TAB2. TRIM5α is well known as an anti-retroviral restriction factor with rhesus macaque 
TRIM5α (RhTRIM5α) binding to the capsid of HIV-1 and disabling the virus at a stage prior to 
integration of the viral genome [55]. In conjunction with this antiviral activity, recognition of HIV-1 
capsid by RhTRIM5α potentiates TRIM5α’s ubiquitin ligase activity, leading to the production of 
unattached K63-linked polyubiquitin chains that activate TAK1 [53]. We found that infection of 
HeLa cells stably expressing RhTRIM5α with VSV-G pseudotyped HIV-1 modestly increased 
the abundance of both p62 bodies (Fig. 5F) and the protein levels of TAK1 and TAB2 (Fig. 5G). 
Thus, our data show that HIV-1 detection by RhTRIM5α promotes p62 coalescence and the 
protection of TAK1 complexes from degradation. Together, these results support a model in 
which p62 localization to cytoplasmic bodies spares TAK1 from autophagic degradation under 
conditions favoring TAK1 signaling.  
p62 promotes the assembly of active TAK1 complexes 
Given our findings that p62 promotes the autophagic degradation of TAK1 complexes 
and that inhibition of autophagy by Beclin 1 knockdown enhances signaling through the TLR3-
TAK1 axis, we expected that p62 knockdown would also enhance the responsiveness of TLR3 
reporter cells to poly(I:C). However, we found that p62 knockdown reduced the activation of NF-
κB/AP1 transcriptional activity upon stimulation (Fig. 6A). This hinted that p62 may also play a 
positive role in TAK1 signaling in addition to the inhibitory role described above. Accordingly, we 
found that p62 knockdown prevented the formation of TAK1/TAB2 complexes (Fig. 6B). For 
these experiments, we used the lysosomotropic compound L-Leucycl-L-Leucine methyl ester 
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(LLOMe) since it potently activates both autophagy [56] and inflammation [57] by inducing 
lysosomal damage. LLOMe treatment also strongly induces p62 bodies in a TAK1-dependent 
manner (Fig. 6C,D). The assembly of TAK1/TAB2 complexes is promoted by LLOMe treatment 
in cells subjected to control knockdown (Fig. 6B). However, in p62 knockdown cells, TAB2 is 
less efficient at immunoprecipitating TAK1 under both control and LLOMe conditions, 
demonstrating a role for p62 in TAK1 complex formation and activation. We also saw a 
reduction of TAK1-TAB2 complex formation in HEK293T cells in which p62 had been deleted by 
CRISPR/Cas9 (Fig. 6E). Restoration of wild type p62, but not of body-deficient PB1-deleted 
p62, restored the assembly of TAK1-TAB2 complex formation in these cells. Assembly of active 
TAK1 complexes requires TAK1 and TAB2 binding to ubiquitin. We found that knocking down 
p62 slightly reduced the interaction between ubiquitin and both TAK1 and TAB2 in co-
immunoprecipitation studies (Fig. EV5G). These results demonstrate that p62 promotes the 
assembly of active TAK1 complexes, thus playing a positive role in TAK1 signaling in addition to 





 In this study, we have shown that TAK1 controls the activities of p62, transitioning it 
away from functioning as a selective autophagy receptor and instead directing it towards 
promoting cellular signaling. Under stress conditions, TAK1 promotes  p62 phosphorylation and 
drives its coalescence into cytoplasmic bodies, sparing it from autophagic degradation. This 
antagonizes p62’s activities as an autophagy receptor, reducing the selective elimination of 
TAK1 complex components. When not acting as an autophagy receptor, p62 facilitates the 
formation of active TAK1 complexes. The requirement for p62 in TAK1 activation is in line with 
previous reports of p62 enhancing NF-κB activation in response to a variety of stimuli 
[21,25,26], as TAK1 is upstream of NF-κB. Overall, our findings mirror the results of a recent 
report in which p62 is switched from autophagy action to a signaling role, albeit by a different 
mechanism involving caspase 8-dependent cleavage [58].  
 On the surface, our data may seem counterintuitive. For instance, the conditions that 
induce p62 body formation (e.g. mTOR inhibition with pp242, lysosomal damage, etc.) also 
induce autophagy and consequent lysosomal degradation of p62. Furthermore, while we show 
here that TAK1 and TRIM5α protect p62 from autophagic degradation, it is known that both of 
these factors promote autophagy initiation [8,9,49,59]. We argue that our findings are consistent 
with a model in which TAK1 and upstream factors like TRIM5α both activate autophagy while 
simultaneously protecting a subset of substrates that otherwise would be depleted from the cell 
by induced autophagy. This mechanism, which we refer to as ‘deselective autophagy’, likely 
confers a negative selection capacity to the autophagy machinery beyond the positive selection 
carried out by autophagy receptors and allows the cell more precise control over which 
substrates are subject to degradation at a given time. 
A recent study suggests that yeast may protect key enzymes from proteolysis during 
stress conditions by a mechanism analogous to what we propose here for TAK1 complexes 
[60]. In this system, the yeast pyruvate kinase (Cdc19) forms degradation-resistant coalesced 
structures in response to glucose starvation. Re-supplementation of glucose disassembles 
these structures, yielding functional Cdc19 enzyme. The inability of yeast cells to generate 
these structures during stress depletes the cells of Cdc19, delaying their re-entry into the cell 
cycle after being returned to favorable growth conditions. Here, we see coalesced structures 
(bodies) containing p62, TAK1, and TAB2 forming in response to a number of stresses. 
Assembly of these structures correlates with protection of their constituent proteins from 
degradation. Given our finding that p62 contributes to TAK1 activation we speculate that p62 
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bodies are the sites where signal transduction takes place in a manner analogous to ASC 
specks involved in inflammasome function. This notion is further supported by the fact that the 
PB1 domain of p62, which we found to be required for its interactions with TAK1 and TAB2, is 
also required for p62 body formation [34] and for p62 signaling activities [61]. Further study is 
required to determine how p62 bodies are resolved after being formed, as it is not known if they 
disassemble analogously to what is seen with Cdc19 or if they are somehow ‘licensed’ to 
undergo autophagic removal. 
The relationships seen here between TAK1 signaling, selective autophagy, and p62 are 
likely relevant to the large number of important biological processes that require TAK1 including 
T cell activation, inflammatory cytokine signaling, and pathogen detection; the latter exemplified 
here with the retroviral sensing factor RhTRIM5α and HIV-1. In this case, TRIM5α was found to 
contribute to p62 body formation in response to pp242 and to protect p62, TAK1, and TAB2 
from starvation-induced autophagic degradation. Activation of RhTRIM5α by HIV-1 capsid 
increased the abundance of p62 bodies and of cellular TAK1 and TAB2. TAK1 signaling 
contributes to HIV-1 capsid-specific restriction by RhTRIM5α [53], a process that is partly p62-
dependent [52]. One important question is why pro-autophagy and pro-inflammatory pathways 
are so tightly linked with p62 at the intersection of the two. A possible explanation for the 
circuitry identified here is that it could help the cell prevent aberrant inflammatory signaling 
under normal conditions by the constitutive degradation of signaling factors such as TAK1 
through basal autophagy while maintaining the cell’s ability to mount a robust response under 
stress conditions that also activate autophagy. Further studies will be necessary to determine if 
p62 body formation protects other immunity-related signaling factors in addition to TAK1 (e.g. 
RIPK1).  
Our study raises a number of mechanistic questions. Foremost among these is how 
TAK1 drives p62 body formation. Our studies demonstrated that TAK1 kinase activity is required 
for p62 body formation and that TAK1 increases p62 phosphorylation at several sites. Among 
these, phosphorylation of Ser-403 has previously been implicated in promoting p62 body 
formation [42]. TAK1 also mediates phosphorylation of Ser-349 [43]. This will recruit KEAP1 and 
Cul3, which may increase p62 body formation by promoting ubiquitination of p62 at lysine-420 
and consequently disrupting the inhibitory dimerization of the p62 UBA domain [62]. However, 
TAK1 may also affect p62 body formation through additional modifications since we found that 
another kinase (TBK1), known to phosphorylate p62 at both Ser-349 and Ser-403 [13,15], is 
dispensable for p62 body formation in response to pp242 treatment. It remains unclear if TAK1 
15 
 
is the kinase directly responsible for p62 phosphorylation or if it is carried out by kinases acting 
downstream of TAK1 (such as p38 MAP kinases [63,64]). Further study will also be necessary 
to determine how p62 scaffolds TAK1 activation. However, since p62 interacts with a wide 
variety of ubiquitin ligases including TRAF6 [22], members of the TRIM and Cullin families 
[28,49], and SMURF1 [65], a likely explanation is that p62 may stabilize interactions between 
TAK1 and upstream ubiquitin E3 ligases that promote TAK1 activation. 
In conclusion, our study demonstrates that TAK1 governs p62 localization and affects 
the balance between p62’s autophagy- and signaling-related functions (Fig. 6F). These actions 
may underlie the ability of the cell to optimize inflammatory signaling responses and reveal a 




MATERIALS AND METHODS 
Cells and viruses 
HeLa and HEK293T were obtained from ATCC and were cultured in DMEM containing 10% 
fetal calf serum and 100 U ml-1 penicillin and streptomycin. HeLa cells stably expressing HA-
tagged RhTRIM5α were obtained from NIH AIDS reagents and were maintained in the above 
media supplemented with puromycin (1 µg ml-1). ULK1/ULK2 knockout MEFs (gift from Sharon 
Tooze) and TAB2 knockout MEFs (gift from Shizuo Akira) along with corresponding wild type 
MEFs were cultured in DMEM containing 10% fetal calf serum supplemented with sodium 
pyruvate and non-essential amino acids. HEK Blue hTLR3 cells (Invivogen) were cultured 
according to manufacturer recommendations. Detection of TLR3 signaling in these cells was 
performed using the HEK-Blue assay according to the manufacturer’s protocol (Invivogen). 
VSV-G pseudotyped HIV-1 (NL43 strain) was collected from the supernatants of HEK293T cells 
transfected with plasmids encoding VSV-G and HIV-1 lacking the Env gene. p62 knockout cells 
were generated in a HEK293T background by transfection with Sqstm1 CRISPR/Cas9 plasmid 
and a Sqstm1 homology directed DNA-repair plasmid (Santa Cruz Biotechnology) that inserts 
RFP and puromycin resistance genes into the Cas9 cut site in Sqstm1. RFP-positive cells were 
sorted and then maintained in the presence of puromycin (1 μg ml-1) and tested for loss of p62 
expression by immunoblot.  
Plasmids, siRNA, and transfection 
TAK1 and TAB2 were PCR amplified from commercially available cDNA clones and recombined 
into pDONR221 using the BP reaction (Life Tech) prior to being recombined into pDest 
expression plasmids by LR cloning. All other plasmids have been previously published [66]. All 
siRNA smart pools were from Dharmacon. With the exception of the siRNA transfections for the 
TRIM screen (with siRNA pre-printed into the 96 well plates and transfected using Dharmafect 
reagent), siRNA were delivered to cells using Lipofectamine 2000 (Life Tech). Plasmid 
transfections were performed by either CaPO4 or Lipofectamine 2000. Samples were prepared 
for analysis the day after DNA transfection. For siRNA experiments, samples were prepared 48 
h after siRNA transfection.  
Treatments, inhibitors, and HIV-1 infections 
Amino acid starvation was performed using EBSS for 4 h at 37oC. Working concentrations for 
inhibitors were as follows: pp242 (LC labs), 10 μg ml-1; bafilomycin A1 (Invivogen), 60 ng ml-1; 
puromycin (Sigma), 5 μg ml-1; LLOMe (MP Biomedicals), 1 mM; BX-795 (Sigma), 10 nM; (5Z)-7-
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Oxozeaenol (Tocris); 10 µM; poly(I:C) high molecular weight (Invivogen), 1 µg ml-1; MG132 
(Selleckchem), 20 µM. Infections with pseudotyped HIV-1 were performed as previously 
described [49]. Briefly, RhTRIM5α expressing cells were incubated with pseudovirus (1.5 ng 
HIV-1 p24 ml-1 in complete media) for 1 h at 4° C to allow virus to bind. Free virus was then 
removed by washing and cells were incubated for 3 h in complete media prior to fixation or 
harvest. For mock infections, cell culture supernatant from untransfected HEK293T was diluted 
in complete media instead of pseudovirus-containing supernatants. For imaging experiments 
with HIV-1 infection, the virus-containing media was supplemented with DAEA-Dextran 10 µg 
ml-1).  
Coimmunoprecipitation and immunoblotting 
Most immunoprecipitation, immunofluorescent labeling, and immunoblots were as described 
[49,67]. For whole cell lysates, cell lysis was performed with a modified RIPA buffer containing 
0.5% NP-40, 1% Triton X-100, and 0.5% SDS. For immunoprecipitation, cell lysis was 
performed with a buffer containing 1% NP-40. Lysis buffers contained protease inhibitor 
cocktails (Roche), phosphatase inhibitor cocktails (Roche) and phenylmethylsulfonyl fluoride 
(PMSF; 1 mM). Primary antibodies used were: Flag (Sigma), p62 (BD or Cell Signaling), GFP 
(Abcam), mCherry (Abcam), actin (Santa Cruz), ubiquitin (MBL), LC3B (MBL), NBR1 (Santa 
Cruz), TAK1 (Cell Signaling), TAB2 (Cell Signaling), phospho-TAK1 (Cell Signaling and 
Invitrogen), UBC13 (Abcam), ATG7 (Cell Signaling), Beclin 1 (Santa Cruz and Cell Signaling), 
HA (Abcam), phospho-p62 (Cell Signaling). Secondary antibodies used were HRP-conjugated 
goat anti-mouse and goat anti-rabbit (Bio-Rad), fluorescently conjugated goat anti-mouse and 
goat anti-rabbit (Licor), or Clean-Blot HRP (Thermo Fisher). All densitomentric quantitation of 
immunoblot signals were normalized to actin.  
High content imaging  
All high content experiments were performed on HeLa cells in 96 well plate format. Following 
the indicated treatments, cells were fixed with 4% paraformaldehyde, permeabilized with 
saponin (0.2%), and immunofluorescently labeled. High content imaging and analysis was 
performed using a Cellomics HCS scanner and iDEV software (Thermo) >500 cells were 
analyzed per treatment in quadruplicate per experiment. Cell outlines were automatically 
determined based on background nuclear staining with Hoechst 33342. The Colocalization 
BioApp was used for assays involving the quantitation of defined puncta/bodies (e.g. p62, 
ubiquitin) and for evaluating colocalization (Pearson’s coefficient). Results are presented either 
as the mean number of puncta/bodies per cell or the total cross-sectional area (in µm2) of 
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puncta per cell. The SpotDetector BioApp was used for measuring the total anti-p62 
fluorescence per cell.  
siRNA screen of TRIMs for roles in p62 body formation 
HeLa cells were cultured in 96-well plates containing siRNA smart pools against a subset of 
human TRIMs (or control siRNAs) and transfection reagent (Dharmacon) as described [51]. 48 
h after plating, the cells were treated with pp242 for 30 minutes prior to fixation with 
paraformaldehyde. Cells were stained with Hoechst 33342 and antibodies as indicated. High 
content imaging was performed as described above. TRIMs whose knockdowns increased or 
decreased the number of p62 body per cell by > 3 SD from the mean of non-targeting siRNA 
controls in two out of two experiments were considered hits.  
Confocal microscopy 
Cells were cultured on glass coverslips prior to being subjected to the indicated treatment. 
Samples were fixed with paraformaldehyde and permeabolized with saponin prior to labeling 
with the indicated antibodies. Images were acquired using a LSM510 Meta confocal microscope 
(Zeiss). For FRAP experiments, we used a Zeiss LSM800 microscope outfitted with live cell 
imaging capabilities and analyzed using Zen2 software (Zeiss). 
Mass spectroscopy 
HEK293T cells were transiently transfected with FLAG-p62 and either GFP-TAK1 or GFP alone. 
Cells were lysed and subjected to immunoprecipitation with anti-FLAG. Immunoprecipitated 
material was then separate by SDS-PAGE and detected by colloidal blue stainining 
(ThermoFisher). The ~65 kDa FLAG-p62 band was excised from the gels and proteolytically 
digested in-gel with trypsin as described [68]. Digested peptides were analyzed by LC-MS/MS 
on a Thermo Scientific Q Exactive Plus Orbitrap Mass Spectrometer in conjunction with an 
EASY-nLC 1200 UHPLC and Proxeon nanospray source operating in positive ionization mode. 
Peptides were loaded on a 100 µm x 25 mm Magic C18 100Å 5U reverse phase trap before 
being separated using a 75 µm x 150 mm Magic C18 200Å 3U reverse phase column.  Peptides 
were eluted with an increasing percentage of acetonitrile over the course of a 90 min gradient 
with a flow rate of 300 nl/min. An MS survey scan was obtained for the m/z range 350-1600 and 
acquired with a resolution of 70,000 and a target of 1X10^6 ions or a maximum injection time of 
30 msec. MS/MS spectra were acquired using a top 15 method where the top 15 ions in the MS 
spectra were subjected to HCD (High Energy Collisional Dissociation).  MS/MS spectra were 
acquired with a resolution of 17,500 and a target of 5X10^4 ions or a maximum injection time of 
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50 msec. An isolation mass window of 1.6 m/z was used for precursor ion selection, charge 
states 2-4 were accepted, and a normalized collision energy of 27% was used for 
fragmentation. A 20 sec duration was used for dynamic exclusion.  
Raw DDA files were searched with Andromeda in MaxQuant (version 1.6.2.3) using default 
Orbitrap settings. Briefly, a target-decoy search strategy was utilized against a human protein 
sequence database (downloaded March 4, 2019 from Uniprot.org) consisting of 73,948 protein 
sequences amended with 49 potential contaminants from the cRAP database of common 
laboratory contaminants (www.thegpm.org/crap) and an equal number of reverse decoys. 
Identifications were made at 1% protein, peptide, and site FDR with match between runs and 
second peptides enabled. Searches were configured for trypsin allowing for 2 missed cleavages 
and carbamidomethylation of Cys as a fixed modification. Up to 5 variable modifications were 
allowed per peptide including: oxidation of Met and Trp, n-terminal acetylation, and 
phosphorylation of Ser, Thr, and Tyr. Instrument parameters and match tolerances were set to 
Orbitrap defaults. Protein level label-free quantitation was performed with the fast MaxLFQ 
algorithm using unique and razor peptides (not containing variable modifications) with a 
requirement for one shared peptide and large LFQ ratio stabilization enabled. 
For total protein level differences, MaxQuant data output was loaded into Perseus version 
1.6.0.2 for further processing and statistics. Proteins designated as reverse, contaminant, or 
only identified through a post-translational modification site were removed from further 
processing. For identification, proteins required identification by at least 1 non-redundant 
peptide (unique or razor) with MS/MS identification or matching. For quantitation, normalized 
LFQ protein intensities were used allowing for matching with a minimum of 3 non-zero values 
from at least one group required to be considered valid. Intensity values were log base 2 
transformed and remaining missing values imputed. For differential protein abundance between 
groups (TAK1 vs GFP control), a Student’s t-test was performed with Benjamini-Hochberg (BH) 
FDR multiple testing correction using a significance threshold of 0.05. Utilizing this testing for 
total protein level differences, we determined that (as expected) only TAK1 and not p62 
(SQSTM1) protein levels were statistically different between our 2 sample populations. 
For peptide level phosphorylation site identification, site specificity required a localization 
probability of at least 95%. For quantitation, phospho-site intensities were averaged (requiring at 
least 3 valid values in at least one group) and significance tested with a one or two sample t-test 
with a significance threshold of 0.05. Scaffold (version 4.8.4, Proteome Software Inc., Portland, 
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OR) was used to manually validate MS/MS based phospho-peptide identifications and neutral 
losses. 
Quantitative RT PCR 
Total RNA was isolated from transfected cells using the TRIZOL method (Life Technologies) 
and reverse transcribed into cDNA using random hexamers as primers (HiCapacity cDNA 
Reverse Transcriptase Kit, ThermoFisher). qPCR was performed using a StepOne Plus 
instrument (Applied Biosystems) relative to 18S rRNA as a housekeeping gene control for 
normalization. The qPCR assays used were obtained from ThermoFisher (18S, Fn0464250_s1; 
SQSTM1 (p62), Hs01061917_g1; MAP3K7 (TAK1), Hs00177373_m1). 
Statistical analysis 
Two-tailed T tests or ANOVA with Bonferroni post hoc analysis were used to test for statistical 
significance, which is determined to by P < 0.05 from three or more independent experiments. 
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Figure 1. TAK1 enhances p62 phosphorylation and promotes the formation of p62 
bodies.  
(A)  High content imaging of p62 in HeLa cells subjected to control or TAK1 siRNA and 
stimulated or not with pp242 for 1 h. White mask, cell boundary. Yellow mask, automatically 
identified p62 bodies. Scale bar, 10 µm. Immunoblots showing knockdown efficiency are shown 
in Fig. EV1E.  
(B-D) High content microscopic analysis of the effect of TAK1 knockdown on the formation of 
ubiquitin puncta in response to puromycin treatment. HeLa cells were subjected to control or 
TAK1 knockdown prior to being treated for 2 h with puromycin. Cells were then stained with 
anti- multi-ubiquitin (green) and anti-p62 (red), and imaged with the abundance of ubiquitin 
puncta and p62 bodies per cell determined by automated image analysis. Scale bar, 10 µm  The 
number of ubiquitin puncta (C) and p62 bodies (D) per cell were determined by image analysis.  
(E) The effect of knocking down TAK1 upstream factors UBC13 and TRAF6 on p62 body 
formation in HeLa cells under basal conditions. Cells were subjected to the indicated 
knockdowns, stained with anti-p62, and images acquired by high content microscopy. Scale bar, 
10 µm. Quantitation of analyzed images is shown in the plot to the right. Immunoblots showing 
knockdown efficiency are shown in Fig. EV1H.  
(F)  The effect of selective TAK1 inhibitor (5Z)-7-oxozeaenol (5Z) on the abundance of p62 
bodies in HeLa cells treated or not with pp242 for 1 h as determined by high content imaging 
and analysis.  
(G)  The effect of GFP-TAK1 expression on the abundance of p62 bodies in HeLa cells. Cells 
were transfected with GFP-TAK1 or GFP alone, stained with anti-p62, and the abundance of 
p62 bodies was determined by high content imaging. Scale bar, 10 µm.  
(H) Immunoblot analysis of the effect of TAK1 knockdown on the abundance of p62 
phosphorylated at serine 403. Numbers indicate the relative abundance of phospho-p62 
normalized to actin loading control. 
(I,J) Phospho-proteomic analysis of immunoprecipitated FLAG-p62 from lysates of HEK293T 
cells expressing GFP-TAK1 or GFP alone. Data shown indicate the intensity of phospho-peptide 
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peaks at p62 Ser24 (I) or Ser226 (J). The total abundance of p62 in the samples was 
determined to be equivalent (see methods), thus no further normalization was needed.  
Data information: Data, mean ± SEM; *, P < 0.05 by Student’s t test (G, I, J) or ANOVA with 
Bonferroni correction (A, C, D, E); †, not significant; N ≥ 3. 
 
Figure 2. TAK1 protects p62 from autophagic degradation.  
(A,B) The effect of TAK1 knockdown on the abundance of autophagy substrates p62 and 
NBR1 under induced autophagy conditions. HeLa cells were subjected to control or TAK1 
knockdown and subjected to amino acid starvation for 4 h in the presence or absence of 
autophagy inhibitor bafilomycin A1 (BafA1) prior to lysis and immunoblotting with the indicated 
antibodies. The relative abundance of p62 or NBR1 following normalization to an actin loading 
control are shown in (B), points show data from independent biological replicates. 
 (C-D)  The effect of WT or kinase dead TAK1 expression on the autophagic degradation of p62. 
HEK293T cells were transfected with the indicated plasmids and then treated or not with 
bafilomycin A1 (BafA1) for 3 h under amino acid starvation conditions. Relative p62 levels were 
normalized to actin loading control and plotted in E. Data points show results from independent 
biological replicates.  
(E) Co-immunoprecipitation analysis of interactions between FLAG-p62 and LC3B from 
lysates of transfected HEK293T cells.  
(F) High content-imaging based analysis of LC3B positivity of cytoplasmic structures 
identified as p62+GFP-TAK1+ or p62+GFP-TAK1negative in transfected HeLa cells. See also Figure 
EV3D,E.  
Data information: Data, mean ± SEM; *, P < 0.05 by Student’s t test (F) or ANOVA with 
Bonferroni correction (B, D); †, not significant; N ≥ 3. 
 




(A) Co-immunoprecipitation analysis of interactions between mCherry-p62 and GFP-TAB2 
from lysates of transfected HEK293T cells treated or not with pp242 for 1 h.  
(B) Co-immunoprecipitation analysis of interactions between mCherry-p62 and GFP-TAB2 
from lysates of transfected HEK293T cells subjected to either control or UBC13 siRNA and 
treated with pp242 for 1 h.  
(C,D) Coimmunoprecipitation analysis of the p62 domains required for binding to TAK1. 
HEK293T cells were transfected with GFP alone, GFP-p62 WT, or domain deletions (C, left) 
and FLAG-TAK1 and treated with pp242 for 1 h prior to cell lysis and immunoprecipitation with 
anti-GFP (D). GFP-p62 constructs showing robust binding to TAK1 or TAB2 are indicated with a 
“+”, marginal binding is indicated with “+/-“, and no binding indicated with “-“ (C, right).  
(E) Confocal microscopic analysis of colocalization between GFP-TAK1, mCherry-TAB2, 
and endogenous p62 in HeLa cells. Inset shows a zoomed in image of the region inside the 
dash-lined box. Scale bar, 5 µm.  
 
Figure 4. TAK1 complex components are substrates of p62-dependent selective 
autophagy.  
(A) Confocal microscopic analysis of co-localization between GFP-TAB2 and 
autophagosome marker LC3B in HeLa cells treated with pp242 for 1 h. Inset shows a zoomed in 
image of the region inside the dash-lined box. Scale bar, 5 µm.  
(B) Triple-colocalization analysis of GFP-TAK1, mCherry-TAB2, and LC3 in HeLa cells 
treated with pp242 for 1 h. Boxed region ii is shown in intensity profile below. A zoomed-in view 
of the contents of boxed region i is shown in the inset. Scale bar, 5 µm.  
(C) Tandem fluorescence analysis of TAB2 localization to acidified compartments in cells 
under basal autophagy conditions. mCherry-eGFP-TAB2 was expressed in HeLa cells and 
analyzed by confocal microscopy (left). Right, the ‘red’ and ‘green’ intensity of each pixel in the 
image are plotted. Lassoed area shows pixels with high red but low green pixel intensities, 
suggesting lysosomal localization. Scale bar, 5 µm.  
(D) Effect of bafilomycin A1 (Baf A1) treatment on the levels of the indicated proteins. HeLa 
cells were treated with Baf A1 or DMSO vehicle for 4 h under amino acid starvation conditions 
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prior to cell lysis and immunoblotting. Graph indicates the relative abundance of each protein as 
determined by densitometry using actin as a loading control and normalizing to DMSO.  
(E) The effect of p62 or UBC13 knockdown on the abundance of TAK1 and TAB2 in HeLa 
cells subjected to amino acid starvation and treated or not with bafilomycin A1 (BafA1) for 4 h. 
Graph indicates the relative abundance of TAK1 or TAB2 as determined by densitometry with 
data points representing independent biological replicates.  
(F) The effect of autophagy inhibition by Beclin 1 knockdown on signaling through the 
TLR3/TAK1 axis. TLR3 reporter cells were transfected with control siRNA or siRNA targeting 
Beclin 1 and treated or not with 1 µg ml-1 poly(I:C) overnight prior to determining the abundance 
of a chromogenic substrate. Shown, one representative experiment out of five.  
Data information: Data, mean ± SEM; *, P < 0.05 by ANOVA with Bonferroni correction; †, not 
significant; N ≥ 3. 
 
Figure 5. TAK1 protects itself from autophagic degradation by driving p62 body 
formation.  
(A) The effect of p62 over-expression on endogenous TAK1 protein levels in HEK293T cells. 
Cells were transfected with either mCherry-p62 or mCherry alone prior to lysis and 
immunoblotting with the indicated antibodies. Graph shows the relative abundance of TAK1 
relative to actin loading control.  
(B) The effect of p62 body-deficient mutant ΔPB1 on the abundance of TAK1 in transiently 
transfected HEK293T cells. Plot, quantitation of the abundance of FLAG-TAK1 as determined 
by densitometry relative to actin, data points each represent independent biological replicates.  
(C) siRNA screen of TRIM E3 ligases for roles in pp242-induced p62 body formation in HeLa 
cells. Numbers indicate TRIM knockdowns that changed the abundance of p62 bodies by >3 SD 
(black lines) from cells transfected with control siRNA (black diamonds, left) in two out of two 
experiments. LC3B, knockdown of LC3B. Shown, one representative experiment out of two. All 
‘hits’ shown were also ‘hits’ in the other experiment.  
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(D) High content imaging and analysis of p62 bodies in HeLa cells subjected to control or 
TRIM5α knockdown under pp242-induced (1 h) conditions. White mask, cell outline; yellow 
mask, p62 bodies. Scale bar, 10 µm.   
(E) The effect of TRIM5α knockdown on the abundance of the indicated proteins. Following 
control or TRIM5α knockdown, cells were starved and treated or not with bafilomycin A1 (BafA1) 
for 4 h prior to lysis and immunoblotting. Plot shows the abundance of the indicated proteins 
relative to actin.  
(F, G) The effect of HIV-1 capsid on p62 coalescence and the abundance of TAK1, TAB2, and 
p62 in HeLa cells stably expressing RhTRIM5α-HA. Cells were exposed to VSV-G pseudotyped 
HIV-1 (NL43 strain) for 1 h at 4°C and then 3 h at 37° C prior to being fixed and prepared for 
high content imaging of p62 bodies (F) or lysis and immunoblotting with the indicated antibodies 
(G).  
Data information: Data, mean ± SEM; *, P < 0.05 by Student’s t test (A, D, F) or ANOVA with 
Bonferroni correction (B, E, G); †, not significant; N ≥ 3. 
 
Figure 6. p62 promotes TAK1 activation.  
(A) The effect of p62 knockdown on signaling through the TLR3/TAK1 axis. TLR3 reporter 
cells were transfected with p62 or non-targeting control siRNA and treated or not with 1 µg ml-1 
poly(I:C) overnight prior to determining the abundance of a chromogenic substrate. Shown, one 
representative experiment out of four.  
(B)  Co-immunoprecipitation analysis of the effect of p62 knockdown on the formation of 
active TAK1 complexes in control HEK293T cells and in cells treated with LLOMe for 1 h.  
(C-D) High content imaging based analysis of the effect of TAK1 knockdown on LLOMe-
induced p62 bodies. HeLa cells were transfected with control or TAK1 siRNA prior to 1 h 
treatment with LLOMe. White mask, cell outline; green mask, p62 body; scale bar, 10 µm.  
(E) Co-immunoprecipitation analysis of the effect of wild type or ΔPB1 p62 expression on 
the interaction between TAK1 or TAB2. Control or p62 knock-out HEK293T were transfected 
with GFP or GFP-tagged p62 as indicated and treated with LLOMe for 1 h prior to lysis and 
immunoprecipitation with anti-TAB2.  
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(F) Model of p62 and TAK1 co-regulation. Top: p62 puncta in cells include autophagosomes 
(LC3B-positive) and signalosomes (TAK1-positive). TAK1 interferes with p62-LC3B interactions. 
Bottom: under stress conditions, p62 signalosomes form in a TAK1 dependent manner.  
Data information: Data, mean ± SEM; *, P < 0.05 by ANOVA with Bonferroni correction; †, not 
significant; N ≥ 3. 
 
EXPANDED VIEW FIGURES 
Figure EV1. TAK1 promotes p62 body formation.  
(A) High content imaging of the effects of pp242 treatment on the number of p62 bodies per 
cell under basal and pp242-induced conditions. HeLa cells were treated with pp242 for 1 h prior 
to fixation and staining with anti-p62. White mask, cell boundary. Yellow mask, automatically 
identified p62 bodies. Scale bar, 10 µm. Plots show two readouts of the abundance of p62 
bodies per cell: the number of p62 bodies and the total cross-sectional area of coalesced p62 
(body area).  
(B) High content imaging of the effects of pp242 treatment on the number of ubiquitin puncta 
per cell. HeLa cells were treated or not for 1 h with pp242 and stained with anti-multi-ubiquitin 
(red) and anti-p62 (green). White mask, cell boundary. Red mask, automatically identified 
ubiquitin puncta; green mask, p62 bodies; scale bar, 10 µm. Plots, quantitation of images for the 
number of ubiquitin (left) or p62 (right) puncta per cell.  
(C) The effect of TBK1 inhibitor BX795 (BX) on pp242 induced p62 bodies as determined by 
high content imaging.  
(D) The effect of ULK1 knockdown on the ability of pp242 to induce p62 bodies. Immunoblot 
shows ULK1 knockdown efficiency.  
(E) Top, immunoblot showing TAK1 knockdown efficiency in HeLa cells corresponding to 
Fig 1A. Bottom, plot showing the effect of TAK1 knockdown on p62 protein levels in HeLa cells 
under basal (full media) conditions. Data points represent independent biological replicates. 
(F) The effect of TAK1 knockdown on p62 bodies formed in HeLa cells in response to a 4 h 
treatment with calcium phosphate precipitates (CPP) or puromycin (Puro.). White mask, cell 
boundary. Yellow mask, automatically identified p62 bodies. Scale bar, 10 µm.  
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(G) Analysis of images as in (F).  
(H) Immunoblot showing ATG7, UBC13, and TRAF6 knockdown efficiency in HeLa cells 
corresponding to Fig 1E.  
(I) The effect of knocking down the indicated proteins on p62 body formation. HeLa cells 
were subjected to the indicated siRNA and treated with pp242 for 1 h prior to fixation and anti-
p62 staining. p62 body formation was observed via high content imagining and the average 
area of p62 bodies per cell shown in the graph.  
Data information: Data, mean ± SEM; *, P < 0.05 by Student’s t test (A, B, E) or ANOVA with 
Bonferroni correction (C, D, G, I); †, not significant; N = 3. 
 
Figure EV2. TAK1 activity is required for p62 body formation.  
(A) High content image analysis of colocalization between GFP-TAK1 and endogenous p62 
in HeLa cells. White mask, cell boundary. Yellow mask, automatically identified regions showing 
overlap between GFP-TAK1 and p62 puncta. Scale bar, 10 µm.  
(B) Confocal microscopic analysis of colocalization between GFP-TAK1 and endogenous 
p62 in HeLa cells. A zoomed-in view of the contents of the boxed region is shown in the inset. 
Scale bar, 5 µm.   
(C-E) High content imaging-based analysis of the abundance of p62 bodies (D) and their 
colocalization with GFP-positive profiles (E) in HeLa cells transfected as indicated and showing 
positivity for GFP signal. Representative images (C) show automatically identified cells showing 
GFP-positivity (white mask). Left panels show p62 localization, right panels show p62 (red), 
GFP (green), and DNA (blue). Scale bar, 10 µm.  
(F) The effect of GFP-TAK1 expression on the abundance of phospho-p62. Lysates from 
HEK293T cells expressing FLAG-p62 and GFP-TAK1 or GFP alone were subjected to 
immunoblotting with the indicated antibodies. Plot shows the fold increase in phospho-p62 
levels relative to what is seen in cells expressing GFP alone.  
(G) The effect of WT or kinase-dead (K63W) GFP-TAK1 expression on the abundance of 
phospho-p62 (pThr269/pSer272) in transfected HEK293T cells. Plot shows the abundance of 
phospho-p62 relative to actin loading control.  
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(H) Representative peptide spectrum from mass spectroscopy showing double 
phosphorylation of p62 between amino acids 266 and 277.  
(I) The effect of TAK1 knockdown on the ability of FLAG-p62 to immunoprecipitate 
mCherry-p62 in HEK293T cells.  
(J) The effect of TAK1 knockdown on the ability of HA-ubiquitin (UBQ) to immunoprecipitate 
mCherry-p62 in transfected HEK293T cells.  
Data information: Data, mean ± SEM; *, P < 0.05; †, not significant by ANOVA with Bonferroni 
correction; N = 3.  
 
Figure EV3. TAK1 reduces LC3-p62 interaction and p62 localization to autophagosomes  
(A) The effect of TAK1 over-expression on p62 protein levels in HEK293T cells. Cells were 
transfected with GFP-p62 and either FLAG-TAK1 or empty vector prior to lysis and 
immunoblotting with anti-GFP and anti-FLAG. Plot, quantitation of the abundance of GFP-p62 
relative to actin as determined by densitometry.  
(B) qPCR analysis of the effect of TAK1 expression on the abundance of p62 mRNA. Total 
RNA was harvested from HEK293T cells transfected with GFP-TAK1 or GFP alone and 
subjected to amino acid starvation for 3 hours. 
(C) Co-IP analysis of the effect of WT or kinase-dead (K63W) TAK1 expression on p62-
LC3B complex formation in HEK293T cells.  
(D-E) Confocal microscopic analysis GFP-TAK1, p62, and LC3B in HeLa cells. Panel (D) 
shows the fluorescence intensity profile along the transect (red arrow) of the cell shown in (C). 
Notably, extensive colocalization is seen between red (p62) and green (GFP-TAK1) profiles and 
between red and blue (LC3B) profiles, but not between green and red profiles. Scale bar in 
panel D, 5 µm. 
(F-G) Time course of the effects of pp242 treatment on the abundance of LC3B puncta (E) and 
either punctate or total p62 (F) showing the fold increase in signal relative to what was seen in 
unstimulated control cells. HeLa cells were treated with pp242 or DMSO vehicle for the 
indicated times prior to fixation, staining, and high content imaging. Total p62 was determined 
by measuring the total fluorescent anti-p62 signal per cell.  
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Data information: Data, mean ± SEM; *, P < 0.05; †, not significant; Student’s t test; N = 3. 
 
Figure EV4. TAK1 complex components interact with p62 under p62 body-forming 
conditions.  
(A) HeLa cells were transfected with GFP-tagged TAB2 and treated with pp242 for 40 min 
prior to fixation and immunostaining with anti-p62 and confocal microscopy. Inset shows 
magnified images of the boxed region. Scale bar, 5 µm.  
(B) Effect of UBC13 knockdown on the interaction between endogenous p62 and TAB2 from 
HeLa cell lysates.  
(C) Effect of UBC13 knockdown on the interaction between GFP-TAK1 and mCherry-p62 as 
determined by co-immunoprecipitation using anti-GFP from transfected HEK293T cell lysates 
treated with pp242 for 40 min.  
(D) Co-immunoprecipitation analysis of interactions between FLAG-tagged TAK1 and GFP-
tagged p62, p62 PB1 domain, or GFP alone from lysates of transfected HEK293T cells treated 
with pp242 for 40 minutes.  
(E) Co-immunoprecipitation analysis of p62 domains involved in binding to TAB2 from cell 
lysates of transiently transfected HEK293T cells treated with pp242 for 1 h.  
(F) FRAP analysis of GFP-TAK1 puncta in HeLa cells. Micrographs show two representative 
regions of interest containing GFP-TAK1 puncta prior to photobleaching and during the recovery 
period. Plot shows the relative fluorescence intensity of GFP-TAK1 puncta (N = 134) at different 
time points before and after bleaching. Scale bar, 5 µm. Data, mean ± SEM.  
 
Figure EV5. Autophagy-dependent and autophagy-independent roles of p62 in TAK1 
signaling.  
(A) Confocal microscopic analysis of colocalization between GFP-TAK1, p62, and LC3B in 
HeLa cells. Inset shows an enlarged image of the region bounded by the dashed lines. Arrow, 
punctum showing positivity for GFP-TAK1, p62, and LC3B signals. Scale bar, 5 µm.  
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(B) Tandem fluorescence analysis of TAK1 localization to acidified compartments in cells. 
mCherry-eGFP-TAK1 was expressed in HeLa cells and analyzed by confocal microscopy. 
Intensity profile shows the ‘red’ and ‘green’ intensity of each pixel in the image. Lassoed area 
show pixels with high red but low green pixel intensities, suggesting lysosomal localization. 
Scale bar, 5 µm.  
(C) The effect of the indicated knockdowns on TAK1 and TAB2 abundance in HeLa cells. 
Following knockdown, cells were cultured under amino acid starvation conditions in the 
presence or absence of bafilomycin A1 (BafA1) for 3 h. Plots indicate the abundance of TAK1 
and TAB2 relative to actin with data points representing independent biological replicates.  
(D) HeLa cells were transfected with GFP-p62 or GFP alone, fixed, and stained with anti-
p62. Left, representative image of cells expressing GFP or GFP-p62. Blue mask, cell outline. 
Yellow mask, p62 bodies. Scale bar, 10 µm. Plot, high content imaging and analysis was used 
to determine the fluorescence intensity specifically from coalesced p62 (bodies) or the total anti-
p62 fluorescence intensity, which is the sum of anti-p62 intensity from diffuse and coalesced 
p62. Whereas coalesced p62 contributes ~50% of the anti-p62 intensity in GFP expressing 
cells, coalesced p62 contributes ~80% of the anti-p62 signal in GFP-p62 expressing cells.  
 
(E) Effect of p62 over-expression on the abundance of FLAG-tagged TAK1 in HEK293T 
cells.  
 
(F) Representative confocal microscopic images of the localization pattern of WT GFP-p62 
and of ΔPB1 GFP-p62. Scale bar, 5 µm. 
 
(G) Co-immunoprecipitation analysis of the effect of p62 knockdown on the interaction 
between TAK1 or TAB2 and ubiquitin in HEK293T cell lysates.  
 
Data information: Data, mean ± SEM; *, P < 0.05; †, not significant by Student’s t test (E) or 







Peptide sequence with localization probability 
Mean peak intensity ± S.E.M 
(n = 3) 
P value  
(t test) 
GFP alone GFP-TAK1 
S24 Yes RFS(0.999)FCCS(0.001)PEPEAEAEAAAGPGPCER 1.5e7 ± 2.1e6 3.0e7 ± 3.0e6 0.02 
S226 No AGEARPGPTAES(0.009)AS(0.991)GPS(0.001)EDPSVNFLK N.D. 4.7e6 ± 1.0e5 0.008 
S272 Yes LTPVS(1)PESSSTEEK 7.7e7 ± 1.6e7 5.9e7 ± 1.6e8 0.3 
T269; 
S275 
Yes; No SRLT(1)PVS(0.047)PES(0.951)S(0.002)STEEK N.D. 1.5e7 ± 1.5e7 0.4 
S332 Yes KIALESEGRPEEQMES(0.008)DNCS(0.991)GGDDDWTHLSSK 1.4e6 ± 1.4e6 3.9e6 ± 2.0e6 0.3 
Table 1. p62 peptides containing at least one high confidence (probability ≥ 0.95) phosphorylated residue as determined by mass 
spectroscopy. N.D., not detected.  
 











